New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients – BioSpace

Could gene therapy provide a solution to HIV? A new research project aims to find out.

The National Institutes of Health(NIH) has backed researchers at the University of Southern California and the Fred Hutchison Cancer Center with a five-year, $14.6 million grant to develop a gene therapy that could potentially control HIV without the need for daily medications. Most HIV patients take a well-regimented cocktail of medications each day to control the virus. This therapy could change that. According to an announcement from the Keck School of Medicine at USC, the goal will be to develop a therapy that prepares patients for a stem cell transplantation using their own cells with little to no toxicity, engineers their own stem cells to fight HIV and stimulates those cells to quickly produce new and engineered immune cells once they're reintroduced into the patient. The hematopoietic stem cell transplants, also known as bone marrow transplants, have been used to treat some blood cancers. The idea is to infuse an HIV patient withhealthy donor blood stem cells that can grow into any type of blood or immune cell.

The gene therapy strategy has been inspired by three cases where leukemia patients who also had HIV received blood stem cell transplants from donors who also carried a mutation that confers immunity to HIV. The mutation was in the CCR5 gene, which encodes a receptor that HIV uses to infect immune cells and is present in about 1 percent of the population, USC said.

The program will engineer blood cells to remove CCR5 from a patient's own stem cells.That will be combined with other genetic changes so that the progeny of engineered stem cells will release antibodies and antibody-like molecules that block HIV.

In addition to the potential gene therapy treatment, researchers are also assessing whether or not CAR-T treatments will benefit HIV patients. Researchers from Harvard University developed a Dual CAR T-cell immunotherapy that can potentially help fight HIV infection. First reported by Drug Target Review, the HIV-specific CAR-T cell is being developed to not only target and eliminated HIV-infected cells, but also reproduce in vivo to enable the patients to fight off the infection. HIVs primary target it T cells, which are part of the bodys natural immune response.

Todd Allen, a professor of Medicine at Harvard Medical School, said the Dual CAR-T cell immunotherapy has so far provided a strong, long-lasting response against HIV-infection while being resistant to the virus itself.

According to the report, theDual CAR T cell was developed through the engineering of two CARs into a single T cell. Each of the CARs contained a CD4 protein that allowed it to target HIV-infected cells and a costimulatory domain, which signaled the CAR T cell to increase its immune functions. As DTR reported, the first CAR contained the 4-1BB co-stimulatory domain, which stimulates cell proliferation and persistence, while the second has the CD28 co-stimulatory domain, which increases its ability to kill infected cells.

To protect the CAR-T cells from HIV, the team added the protein C34-CXCR4, which prevents HIV from attaching to and infecting cells. When that was added, the researchers found in animal models that the treatment was long-lived, replicated in response to HIV infection, killed infected cells effectively and was partially resistant to HIV infection.

Still, other researchers are looking to those rare individuals who are infected with HIV but somehow on their own are able to suppress the virus without the need for any treatment. Researchers have sought to replicate what this small percentage of patients can naturally do in other patients who require those daily regimens of medications. Through the sequencing of the genetic material of those rare individuals, researchers made an interesting discovery.

The team discovered large numbers of intact viral sequences in the elite controllers chromosomes. But in this group, the genetic material was restricted to inactive regions, where DNA is not transcribed into RNA to make proteins, MedNewsToday reported.

Now the race is on to determine how this can be replicated and used to treat the nearly 38 million people across the globe who have been diagnosed with HIV.

More:
New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients - BioSpace

Insights on the Global Animal Medicine Market to 2030 – Featuring Zoetis, Boehringer Ingelheim & Bayer Among Others – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Animal Medicine Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global animal medicine market as it emerges from the COVID-19 shut down.

The global animal medicine market is expected to decline from $38.9 billion in 2019 to $32.4 billion in 2020 at a compound annual growth rate (CAGR) of -16.8%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. COVID-19 pandemic is affecting industries across the globe including the animal sector. The restrictions on non-essential medical services coupled with slowed production of veterinary pharmaceuticals due to extended factory closures in various countries, shortage of APIs and other chemicals, and rise in prices of key ingredients are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 7% from 2021 and reach $50.3 billion in 2023.

Reasons to Purchase

North America was the largest region in the global animal medicine market, accounting for 58% of the market in 2019. Asia Pacific was the second largest region accounting for 18% of the global animal medicine market. Africa was the smallest region in the global animal medicine market.

Veterinary pharmaceutical producers have started using Stem Cell Therapy as an animal medicine due to its excellent capabilities of healing arthritis or animal injury. Stem Cell Therapy is a process of injecting stem cell into the body of the animal to replace the damaged cells of the body. The injected stem cell is unspecialized and acquires the property of the cell that has to be replaced. It also divides itself into as many cells as required by the body. It enables to treat the bone and ligament injury, kidney and liver disease and some kinds of skin diseases.

The animal medicine market consists of sales of animal medicine and related services by entities (organizations, sole traders and partnerships) that produce animal medicine to treat animal diseases. This industry includes establishments that produce veterinary pharmaceuticals such as veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals. It also includes establishments that produce medical feed additives and nutritional feed additives.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Animal Medicine Market Characteristics

3.1. Market Definition

3.2. Key Segmentations

4. Animal Medicine Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Animal Medicine Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Animal Medicine Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Animal Medicine Market Trends And Strategies

8. Animal Medicine Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, Value ($ Billion)

8.2.1. Drivers Of The Market

8.2.2. Restraints On The Market

8.3. Forecast Market Growth, Value ($ Billion)

8.3.1. Drivers Of The Market

8.3.2. Restraints On The Market

9. Animal Medicine Market Regional Analysis

9.1. Global Animal Medicine Market, 2019, By Region, Value ($ Billion)

9.2. Global Animal Medicine Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Region

9.3. Global Animal Medicine Market, Growth And Market Share Comparison, By Region

10. Animal Medicine Market Segmentation

10.1. Global Animal Medicine Market, Segmentation By Type

10.2. Global Animal Medicine Market, Segmentation By Type of Animal

10.3. Global Animal Medicine Market, Segmentation By End-Use

11. Animal Medicine Market Segments

11.1. Global Veterinary Pharmaceuticals Market, Segmentation By Type

11.2. Global Feed Additives Market, Segmentation By Type

12. Animal Medicine Market Metrics

12.1. Animal Medicine Market Size, Percentage Of GDP, 2015-2023, Global

12.2. Per Capita Average Animal Medicine Market Expenditure, 2015-2023, Global

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/psh6sd

Here is the original post:
Insights on the Global Animal Medicine Market to 2030 - Featuring Zoetis, Boehringer Ingelheim & Bayer Among Others - ResearchAndMarkets.com -...

Stem Cell And Regenerative Therapy Market Insights And Forecast 2019-2024 – Scientect

Theglobal stem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/11723

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

<<>>https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Follow this link:
Stem Cell And Regenerative Therapy Market Insights And Forecast 2019-2024 - Scientect

Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;…

Sept. 2, 2020 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a consulting role for personal reasons while a search for his replacement is conducted.

With the additions of Lisa and Kevin to our team, Magenta continues to deepen our technical expertise, bolstering our strong discovery, research, development and regulatory leadership to further our goal of delivering curative immune reset to patients in need, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. We are delighted to welcome Lisa and Kevin on board and look forward to their many contributions to the Magenta mission.

As Chief Scientific Officer, Dr. Olson will provide strategic direction, oversight and execution for Magentas research and discovery efforts. This entails driving research strategy as Magenta continues to optimize its preclinical and clinical pipeline. She will join the executive team and will be a key member of the R&D leadership team.

Dr. Olson is an experienced senior-level pharmaceutical executive, with more than 20 years of experience in research and drug discovery. She comes to Magenta following 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions, including new target approval, project advancement and licensing opportunities. Under her leadership, 15 molecules advanced into clinical development, including Upadacitinib that launched last year as Rinvoq. Prior to AbbVie, she served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer, Inc. She began her career as an Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago.

Dr. Olson holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.

As Senior Vice President, Head of Regulatory and Quality, Dr. Johnson will lead Magentas global regulatory strategy for the Companys programs across multiple therapeutic areas. He will also be responsible for the oversight and accountability for all quality activities to enable Good Practice (GxP) functions across the portfolio. In this role, Dr. Johnson will provide strategic guidance and leadership to members of the R&D leadership team and the regulatory and quality teams for Magentas portfolio for all phases of product lifecycle.

Dr. Johnson bring years of regulatory, quality assurance and development leadership, coming to Magenta from Imara, Inc., where he served as Senior Vice President, Regulatory Affairs, Quality and Pharmacovigilance, leading successful requests for several regulatory designations with the U.S. Food and Drug Administration (FDA). Prior to his time at Imara, Dr. Johnson led global regulatory strategy and implementation for breakthrough therapy-designated rare disease development programs at Vtesse, later acquired by Sucampo. He also served as Director, Global Regulatory Affairs for Rare Diseases and Gene Therapies at GlaxoSmithKline, where he was part of on the international regulatory team for the European approval of the gene therapy Strimvelis for ADA-SCID, and subsequently secured Regenerative Medicine Advanced Therapy (RMAT) designation for a retinal gene therapy product.

Dr. Johnson holds a Ph.D. in Neurobiology from the University of North Carolina (UNC) School of Medicine; a Master of Business Administration from the Kenan-Flagler School of Business, UNC; and a Bachelor of Science in Chemistry from the University of South Florida.

Along with these leadership team additions, Magenta also announced today that Jason Ryan, Chief Operating and Financial Officer, will step down from that role at the end of September. He will continue to contribute to Magenta in a consulting capacity, and the Company has commenced a search for a replacement.

Jason has been a dynamic and reliable leader at Magenta since he joined us in 2019, leading finance and operations, contributing to our strategic planning efforts, and spearheading two financings during a period of significant growth, said Gardner. We are truly grateful for his contributions to the patients we seek to serve, our employees and business partners.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005236/en/

Excerpt from:
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;...

BioForward Recognizes Scientific and Business Success with Annual Wisconsin Biohealth Awards – Business Wire

MADISON, Wis.--(BUSINESS WIRE)--BioForward Wisconsin, the collective voice of Wisconsins robust and comprehensive biohealth cluster, representing more than 220 member organizations, has announced the winners of the sixth annual Wisconsin Biohealth Awards.

These awards showcase leadership and innovation in the Wisconsin biohealth industry and specifically recognize scientific and business successes that have brought Wisconsin to be leaders in integrated health solutions.

The 2020 winners of the Hector F. DeLuca Scientific Achievement Award is Dr. Mary Horowitz, and Wisconsin Biohealth Business Achievement Award is Dr. Jim Weber.

Dr. Mary Horowitz is an active blood and marrow transplant physician whose research and dedication to the field of stem cell transplant and hematologic malignancy practice has had a significant impact worldwide. Dr. Horowitz joined the Center for International Blood and Marrow Transplant Research (CIBMTR) in 1985 and has served as its Chief Scientific Director since 1991. Dr. Horowitz is also the Research Director for the Stem Cell Therapeutic Outcomes Database of the C.W. Bill Young Cell Transplantation Program and Principal Investigator of the Data and Coordinating Center of the National Blood and Marrow Transplant Clinical Trials Network. She holds the Robert A. Uihlein Professorship for Hematologic Research at Medical College of Wisconsin and has previously served as Chief of the Division of Hematology and Oncology in MCWs Department of Medicine. Dr. Horowitz has served on numerous NIH review and advisory committees and has been continuously funded by the NIH since 1991. She has co-authored more than 400 peer-reviewed publications.

Dr. James Weber founded PreventionGenetics in 2004 with a vision of "disease prevention through genetic testing." An internationally acclaimed research scientist, Dr. Weber was a major contributor to The Human Genome Project. His discovery of Short Tandem Repeat Polymorphisms (microsatellites) and the creation of the Marshfield Maps of the human genome was a significant advance in human genetics. He has authored or co-authored more than 200 peer-reviewed scientific publications. In 1986, Dr. Weber joined Marshfield Clinic Research Foundation where he was senior research scientist, director of the Center for Medical Genetics and Director of the National Institutes of Health-funded Mammalian Genotyping Service.

"BioForward Wisconsin is excited and honored to announce this year's award winners," said Lisa Johnson, CEO of BioForward. "Dr. Horowitz and Dr. Weber embody the ideal candidate for these awards due to their globally recognized research achievements that have lead to major medical advances in treating diseases and improving health outcomes. These awards are a testament to the ingenuity, passion, and vision of our awardees."

Wisconsin Biohealth Summit, now in a virtual format over September 23, September 30, and October 7, 2020, will reflect the resilience and creativity of the Wisconsin Biohealth Industry. This years award ceremony will be pre-recorded to allow for the full safety of the awardees but will be featured October 7th a viewing party inviting all attendees to celebrate and honor Dr. Horowitz and Dr. Weber.

The Wisconsin Biohealth Summit sponsors include Tommy G. Thompson Center on Public Leadership, ThermoFisher Scientific, Catalent, Exact Sciences, GE Healthcare, Mallinckrodt, WARF, AbbVie, Aurora Health Care, Cellular Dynamics International, Covance, Findorff, Illumina, Isthmus Project, Kraemer Brothers, PhRMA, PPD, Promega, TeraMedica, University Research Park, and Yahara Software.

To learn more about BioForwards annual Wisconsin Biohealth Summit, visit the Summit website here.

About BioForward

BioForward Wisconsin is the collective voice of Wisconsins robust and comprehensive biohealth cluster, which represents more than 220 member organizations across an integrated network of health solution leaders, including research institutions, biotech and biopharma, digital health and medical device and diagnostics. It is an action-oriented association that focuses on initiatives to strengthen the states talent pipeline; collaborations to develop supply chain partnerships; educational and networking events to enhance professional development; and legislative advocacy to highlight the economic and social impact of the biohealth industry on the state, nation, and world. Learn more about BioForward Wisconsin at http://www.bioforward.org.

Read the rest here:
BioForward Recognizes Scientific and Business Success with Annual Wisconsin Biohealth Awards - Business Wire